RaQualia Pharma Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
5/10
|
34.75 | 110.96 | -68.68% | 1314.33 | -97.36% |
| P/S |
|
7.48 | 74.98 | -90.03% |
|
|
| P/BV |
|
2.32 | 70.27 | -96.69% |
|
|
| P/FCF |
|
-17.23 | 85.21 | -120.22% |
|
|
| Ev/Ebitda |
|
-66.87 | 17.08 | -491.59% |
|
|
| Ev/S |
|
5.69 | 72.29 | -92.13% |
|
|
| Ev/FCF |
|
-11.5 | 27.51 | -141.81% |
|
|
| E/P |
|
-0.02 | -0.1872 | -89.32% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-8.51 | -77.56 | -89.03% | 4.04 | -310.54% |
| ROE |
|
-5.29 | -9.31 | -43.2% |
|
|
| ROA |
|
-4.67 | -9.75 | -52.11% |
|
|
| ROIC |
|
0 | 9.09 | -100% |
|
|
| ROS |
|
-17.02 | -144.19 | -88.2% |
|
|
| ROCE |
|
-5.51 | 5.62 | -197.98% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.7168 | -1.04 | -31.18% | -0.8926 | -19.7% |
| Nеt Debt/Ebitda |
|
21 | 12.5 | 67.91% |
|
|
| Debt/Ratio |
|
0.0167 | 0.1401 | -88.06% |
|
|
| Debt/Equity |
|
0.2966 | 24.46 | -98.79% |
|
|
| Debt/Net Income |
|
-0.3583 | -1.96 | -81.7% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 2.66 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 1.28 | -100% | ||
| DSI |
|
0 | 0.7385 | -100% |
|
|
| Average dividend growth |
|
0 | -18.33 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 1.91 | -100% |
|
|
| Average percentage for payments |
|
0 | 33.86 | -100% |
|
|
| Difference from average difference in sector |
|
-2.66 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
2/10
|
11.84 | 106.99 | -88.93% | ||
| Growth impulse Ebitda in 5 years |
|
-197.9 | 90.7 | -318.19% | ||
| Growth impulse Net Income in 5 years |
|
-6206.83 | 77.88 | -8069.74% | ||
| Growth impulse FCF in 5 years |
|
50.48 | 9.1 | 454.73% | ||
| Growth impulse EPS in 5 years |
|
-5872.65 | 9.8 | -60025% |
IP Score
2.89/10
